

E. coli Periprosthetic Joint Infections: Poor Infection Clearance at One Year



Breanna A. Polascik, BS, Mikhail A. Bethell, MS, Edward F. Hendershot, MD, William A. Jiranek, MD, FACS, Jessica L. Seidelman, MD, MPH, Thorsten M. Seyler, MD, PhD

BACKGROUND

- Escherichia Coli (E. coli) is a gram-negative rod that can cause devastating periprosthetic joint infections (PJIs) following total hip and knee replacements (THA/TKA).
- DAIRs, 2-stage revisions, and Arthrodeses/Resection Arthroplasties are all surgical treatment options for E. coli PJIs, but minimal outcomes literature exists.

PURPOSE

- Investigate the outcomes of *E. coli* PJI in patients with THA or TKA.
- We hypothesized that DAIR has inferior outcomes compared to other treatment modalities for THA/TKA *E. coli* PJI.

METHODS

- Retrospective review of Duke's EMR from 2009-2020 identified 21 patients that met MSIS criteria for *E. coli* hip/knee PJI.
- Primary outcome: 1-year infection clearance infection eradication sans antibiotics or further requiring surgery (57.1%) and chronic antibiotics surgeries for 1 year after completion of standard (38.1%). postop antibiotics.
- Minimum follow-up: 1 year.
- Descriptive statistics were used to compare patients with/without the primary outcome.

RESULTS

- The final analysis included 21 patients (mean age 66.6 yrs, 47.6% male, 23.8% non-Caucasian, 38.1% knees).
- There were 11 acute, 8 acute hematogenous, and 2 chronic PJIs.
- Several patients had recent gastrointestinal/urinary tract surgery (14.3%), recurrent urinary tract infections (9.5%), or $\geq 1 E$. coli urine culture ≤ 1 mo pre-PJI (14.3%).

Duke University, Durham, NC

	Overall	Not Clear at 1 Yr	Clear at 1 Yr	p- value		Overall	2-stage	DAIR	Arthrodesis/ Resection*	•
Months from Most Recent	1 [0.58, 9]	0.72 [0.53 <i>,</i> 2.00]	11.50 [7.00,	0.014					Resection	Va
Surgery, median [IQR]			94.00]	0 102	1-year Infection Clearance, n (%)	7 (33.3)	3 (100.0)	1 (7.1)	3 (75.0)	0.(
Symptom Acuity, n (%) Acute	5 (23.8)	4 (28.6)	1 (14.3)	0.103	Treatment Failure at Last	1 1 (C C - 7)	1 (22.2)		1 (25 0)	0
Acute hematogenous	14 (66.7)	10 (71.4)	4 (57.1)		Follow-up, n (%)	14 (66.7)	1 (33.3)	12 (85.7)	1 (25.0)	0.
Chronic	2 (9.5)	0 (0.0)	2 (28.6)		Reinfection Requiring Surgery, n (%)	12 (57.1)	1 (33 3)	10 (71.4)	1 (25.0)	0.
	X 7			0.001	Infection Controlled on Chronic	12 (37.1)	, ,	, , , , , , , , , , , , , , , , , , ,	I (23.0)	0.
Index PJI Procedure, n (%) 2-stage	3 (14.3)	0 (0.0)	3 (42.9)		Antibiotics ^{**} , n (%)	8 (38.1)	0 (0.0)	8 (57.1)	0 (0.0)	0.
DAIR	14 (66.7)	13 (92.9)	1 (14.3)		Death <1 yr, n (%)	1 (4.8)	0 (0.0)	1 (7.1)	0 (0.0)	1.
Arthrodesis/Resection	4 (19.0)	1 (7.1)	3 (42.9)							
Arthroplasty	. (13.0)	- (,)	0 (1210)		Death at Last Follow-up, n (%)	10 (47.6)	1 (33.3)	8 (57.1)	1 (25.0)	0.
TABLE	1. PJI Charao	cteristics			90-day All-Cause Readmission, n (%)	10 (47.6)	0 (0.0)	9 (64.3)	1 (25.0)	0.
 Surgical treatments 		Υ.		U	90-day Orthopaedic	, , ,		, ,	x <i>z</i>	
revision (14.3%), G	irdlestone	Resection	Arthrop	olasty	Readmissions, n (%)	8 (38.1)	0 (0.0)	6 (42.9)	2 (50.0)	0.
(14.3%), and fusion		-	-	-	All-Cause Return to Operating Room, n (%)	15 (71 /)	3 (100.0)	11 (78 6)	1 (25.0)	0.
and 100% 1-year info		<i>,</i>		, and	Recurrent/Persistent <i>E. coli</i> PJI,	13 (71.4)	5 (100.0)	11(78.0)	I (23.0)	0.
33.3% 1-year infectio	on clearand	ce overall (p	=.001).		n (%)	5 (23.8)	1 (33.3)	4 (28.6)	0 (0.0)	0.
			•							
 Of patients who rec 		•	• •	toms	Recurrent/Persistent PJI, n (%)	10 (47.6)	1 (33.3)	9 (64.3)	0 (0.0)	0.
for \leq 1 mo and 42.9% had symptoms for \leq 8 d.				TABLE 2. Outcomes						

- Patients clear at 1 year had a significantly longer mean time from most recent surgery to index PJI surgery (48.7 vs 7mo) and more acute hematogenous than acute or chronic infections (54.6% vs 27.3% vs 18.2%).
- Patients who were not clear at 1 year had significantly infections (80% vs acute 20% more hematogenous).
- The *E. coli* PJI persisted in 23.8% of patients.
- follow-up Outcomes at final Girdlestone/Resection Arthroplasty (28.6%), original prosthetic (28.6%), new prosthetic (19%), above knee amputation (9.5%), destination spacer (9.5%), and arthrodesis (4.8%).

U	Duke Orthopaedics

acute

included

- *E. coli* PJI 1-year infection clearance is poor, with DAIR being the most common yet least effective surgical treatment.
- This may be due to the persistence of *E. coli* biofilms, which may be better removed with prosthetic-extracting surgeries.
- may support the use of 2-stage revisions or • This Arthrodesis/Resection Arthroplasty over DAIRs, when feasible, in patients with *E. coli* PJI.

REFERENCES

1. Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty. 2011 Sep;26(6 Suppl):104-8. Epub 20110608.

2. Ull C, Yilmaz E, Baecker H, Schildhauer TA, Waydhas C, Hamsen U. Microbial findings and the role of difficult-to-treat pathogens in patients with periprosthetic infection admitted to the intensive care unit. Orthop Rev (Pavia). 2020 Nov 24;12(3):8867. Epub 20201124.